Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Other Non-Current Liabilities (2016 - 2025)

Avalo Therapeutics filings provide 11 years of Other Non-Current Liabilities readings, the most recent being $18.0 million for Q4 2025.

  • On a quarterly basis, Other Non-Current Liabilities rose 112.26% to $18.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $18.0 million, a 112.26% increase, with the full-year FY2025 number at $18.0 million, up 112.26% from a year prior.
  • Other Non-Current Liabilities hit $18.0 million in Q4 2025 for Avalo Therapeutics, up from $117000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $18.0 million in Q4 2025 to a low of $117000.0 in Q3 2025.
  • Median Other Non-Current Liabilities over the past 5 years was $1.7 million (2022), compared with a mean of $3.2 million.
  • Biggest five-year swings in Other Non-Current Liabilities: surged 248.07% in 2024 and later crashed 95.15% in 2025.
  • Avalo Therapeutics' Other Non-Current Liabilities stood at $1.4 million in 2021, then increased by 22.56% to $1.7 million in 2022, then soared by 224.37% to $5.6 million in 2023, then skyrocketed by 52.79% to $8.5 million in 2024, then skyrocketed by 112.26% to $18.0 million in 2025.
  • The last three reported values for Other Non-Current Liabilities were $18.0 million (Q4 2025), $117000.0 (Q3 2025), and $197000.0 (Q2 2025) per Business Quant data.